LUTO
MCID: LWR018
MIFTS: 40

Lower Urinary Tract Obstruction, Congenital (LUTO)

Categories: Fetal diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Lower Urinary Tract Obstruction, Congenital

MalaCards integrated aliases for Lower Urinary Tract Obstruction, Congenital:

Name: Lower Urinary Tract Obstruction, Congenital 56 73 6
Luto 56 73
Posterior Urethral Valve 58
Urologic Diseases 43
Puv 58

Characteristics:

Orphanet epidemiological data:

58
posterior urethral valve
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/100000 (Australia); Age of onset: Antenatal,Neonatal; Age of death: early childhood;

OMIM:

56
Inheritance:
autosomal dominant

Miscellaneous:
intrafamilial variability
variable age at onset of symptoms
diagnosed in utero in some patients


Classifications:

Orphanet: 58  
Rare renal diseases
Developmental anomalies during embryogenesis


Summaries for Lower Urinary Tract Obstruction, Congenital

UniProtKB/Swiss-Prot : 73 Lower urinary tract obstruction, congenital: A disorder characterized by urinary bladder outflow obstruction, which can represent an anatomical blockage or a functional obstruction. The most common anatomical causes are posterior urethral valves at the level of the prostatic urethra, a lesion unique to males. Less common are anterior urethral valves, also called urethral atresia, that can occur in either sex. LUTO is an autosomal dominant disease with variable expression.

MalaCards based summary : Lower Urinary Tract Obstruction, Congenital, also known as luto, is related to cakut and congenital anomalies of kidney and urinary tract 2. An important gene associated with Lower Urinary Tract Obstruction, Congenital is BNC2 (Basonuclin 2). The drugs Angiotensin II and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include kidney, prostate and brain, and related phenotypes are recurrent urinary tract infections and congenital posterior urethral valve

OMIM : 56 Congenital lower urinary tract obstruction (LUTO) is characterized by anatomic blockage of bladder outflow due to urethral stenosis, which may be caused by posterior urethral valves in some families (Kolvenbach et al., 2019). (618612)

Related Diseases for Lower Urinary Tract Obstruction, Congenital

Diseases related to Lower Urinary Tract Obstruction, Congenital via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 246)
# Related Disease Score Top Affiliating Genes
1 cakut 11.8
2 congenital anomalies of kidney and urinary tract 2 11.8
3 congenital anomalies of kidney and urinary tract 1 11.6
4 congenital anomalies of kidney and urinary tract 3 11.5
5 urofacial syndrome 1 11.3
6 urinary system disease 11.3
7 binswanger's disease 11.1
8 dementia - subcortical 11.1
9 subcortical arteriosclerotic encephalopathy 11.1
10 vesicoureteral reflux 1 10.9
11 end stage renal disease 10.8
12 acute cystitis 10.8
13 renal dysplasia 10.7
14 kidney disease 10.6
15 urethral stricture 10.6
16 chronic kidney disease 10.6
17 prune belly syndrome 10.5
18 hypospadias 10.4
19 prostatic hypertrophy 10.4
20 cryptorchidism, unilateral or bilateral 10.4
21 prostatic hyperplasia, benign 10.4
22 prostatic adenoma 10.4
23 pyelonephritis 10.4
24 vaccinia 10.4
25 uremia 10.3
26 anterior urethral valve 10.3
27 pneumothorax 10.3
28 duplication of urethra 10.3
29 bladder cancer 10.2
30 oligohydramnios 10.2
31 atresia of urethra 10.2
32 renal hypodysplasia/aplasia 1 10.2
33 anus, imperforate 10.2
34 renal hypoplasia 10.2
35 potter's syndrome 10.2
36 renal tubular acidosis 10.2
37 impotence 10.2
38 orchitis 10.2
39 acute kidney failure 10.2
40 ureteral obstruction 10.2
41 infertility 10.2
42 urethral diverticulum 10.2
43 epididymo-orchitis 10.2
44 47,xyy 10.2
45 patent urachus 10.2
46 cystitis 10.1
47 kidney cancer 10.1
48 urinary tract obstruction 10.1
49 nephrolithiasis 10.1
50 bladder diverticulum 10.1

Graphical network of the top 20 diseases related to Lower Urinary Tract Obstruction, Congenital:



Diseases related to Lower Urinary Tract Obstruction, Congenital

Symptoms & Phenotypes for Lower Urinary Tract Obstruction, Congenital

Human phenotypes related to Lower Urinary Tract Obstruction, Congenital:

58 31 (show all 22)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 recurrent urinary tract infections 58 31 hallmark (90%) Very frequent (99-80%) HP:0000010
2 congenital posterior urethral valve 58 31 hallmark (90%) Very frequent (99-80%) HP:0010957
3 vesicoureteral reflux 58 31 frequent (33%) Frequent (79-30%) HP:0000076
4 hydronephrosis 58 31 frequent (33%) Frequent (79-30%) HP:0000126
5 postnatal growth retardation 58 31 occasional (7.5%) Occasional (29-5%) HP:0008897
6 hypertension 58 31 occasional (7.5%) Occasional (29-5%) HP:0000822
7 urinary incontinence 58 31 occasional (7.5%) Occasional (29-5%) HP:0000020
8 pyelonephritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0012330
9 stage 5 chronic kidney disease 58 31 occasional (7.5%) Occasional (29-5%) HP:0003774
10 fetal pyelectasis 58 31 occasional (7.5%) Occasional (29-5%) HP:0010945
11 enuresis nocturna 58 31 occasional (7.5%) Occasional (29-5%) HP:0010677
12 unilateral renal dysplasia 58 31 occasional (7.5%) Occasional (29-5%) HP:0008718
13 hypertelorism 58 31 very rare (1%) Very rare (<4-1%) HP:0000316
14 abnormal nasal morphology 58 31 very rare (1%) Very rare (<4-1%) HP:0005105
15 retrognathia 58 31 very rare (1%) Very rare (<4-1%) HP:0000278
16 urethral stenosis 58 31 very rare (1%) Very rare (<4-1%) HP:0008661
17 lethargy 58 31 very rare (1%) Very rare (<4-1%) HP:0001254
18 oligohydramnios 58 31 very rare (1%) Very rare (<4-1%) HP:0001562
19 dysuria 58 31 very rare (1%) Very rare (<4-1%) HP:0100518
20 urinary retention 58 31 very rare (1%) Very rare (<4-1%) HP:0000016
21 renal insufficiency 58 Occasional (29-5%)
22 chronic kidney disease 58 Very frequent (99-80%)

Symptoms via clinical synopsis from OMIM:

56
Genitourinary Bladder:
vesicoureteral reflux
urethral stenosis
urinary incontinence
nocturia
posterior urethral valve
more
Genitourinary Kidneys:
renal hypodysplasia (in 1 patient)

Clinical features from OMIM:

618612

Drugs & Therapeutics for Lower Urinary Tract Obstruction, Congenital

Drugs for Lower Urinary Tract Obstruction, Congenital (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
2
leucovorin Approved Phase 4 58-05-9 6006 143
3
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
4
Hydroxychloroquine Approved Phase 4 118-42-3 3652
5
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
6
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
7
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
8
Uric acid Investigational Phase 4 69-93-2 1175
9 Angiotensin II Type 1 Receptor Blockers Phase 4
10 Angiotensinogen Phase 4
11 Angiotensin Receptor Antagonists Phase 4
12 Giapreza Phase 4
13 Antihypertensive Agents Phase 4
14 Hematinics Phase 4
15 Antirheumatic Agents Phase 4
16 Micronutrients Phase 4
17 Trace Elements Phase 4
18 Vitamins Phase 4
19 Antioxidants Phase 4
20 Vitamin B Complex Phase 4
21 Nutrients Phase 4
22 Folate Phase 4
23 Vitamin B9 Phase 4
24 Interferon-alpha Phase 4
25 Antiparasitic Agents Phase 4
26 interferons Phase 4
27 Antiprotozoal Agents Phase 4
28 Immunoglobulin A Phase 4
29 Antimalarials Phase 4
30 Ferric Compounds Phase 4
31 Anticoagulants Phase 4
32 Calcium, Dietary Phase 4
33 Anesthetics Phase 4
34 Anticonvulsants Phase 4
35 Neuromuscular Blocking Agents Phase 4
36 Anesthetics, Local Phase 4
37 Bromides Phase 4
38
Calcium Nutraceutical Phase 4 7440-70-2 271
39
Mirabegron Approved Phase 3 223673-61-8 9865528
40
Tamsulosin Approved, Investigational Phase 3 106133-20-4 129211
41
Propiverine Approved, Investigational Phase 3 60569-19-9 4942
42
tannic acid Approved Phase 3 1401-55-4
43
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
44
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
45
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
46
Lomefloxacin Approved, Investigational Phase 3 98079-51-7 3948
47
Ofloxacin Approved Phase 3 82419-36-1 4583
48
Sodium citrate Approved, Investigational Phase 3 68-04-2
49
Sevelamer Approved Phase 3 52757-95-6
50
Pregabalin Approved, Investigational Phase 3 148553-50-8 5486971

Interventional clinical trials:

(show top 50) (show all 129)
# Name Status NCT ID Phase Drugs
1 Periprocedural Administration of Folic Acid for Prevention of Contrast Induced Nephropathy in Patients Undergoing Coronary CTA/Angiography/Angioplasty Unknown status NCT02444013 Phase 4 Folic acid;Placebo
2 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study Unknown status NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
3 A Long-Term, Open-Label, Prospective Phase IV Study to Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis Completed NCT03256838 Phase 4 Ferric Citrate
4 Efficacy of the Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures Recruiting NCT02805504 Phase 4 Exparel;Marcaine
5 Does Depth of Neuromuscular Blockade (NMB) Affect Surgical Conditions and Postoperative Pain in Obese Patients Undergoing Robotic Surgery Recruiting NCT03591289 Phase 4 NMB with rocuronium bromide
6 Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome Completed NCT00239317 Phase 3 Tamusulosin
7 Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome Completed NCT00239265 Phase 3 Tamuslosin
8 A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy Completed NCT01638000 Phase 3 Mirabegron;Solifenacin succinate
9 Efficacy and Tolerability of Propiverine Hydrochloride Extended Release (ER) Compared to Immediate Release (IR) in Patients With Neurogenic Detrusor Overactivity. A Randomized, Double Blind, Parallel Group, Multicenter Clinical Trial Completed NCT01530620 Phase 3 Propiverine hydrochloride ER (extended release);Propiverine hydrochloride IR (immediate release)
10 A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder Completed NCT01972841 Phase 3 Solifenacin succinate;Mirabegron;Placebo to match solifenacin succinate;Placebo to match mirabegron
11 An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder Completed NCT03492281 Phase 3 vibegron;Vibegron placebo;Tolterodine Tartrate ER;Tolterodine placebo
12 An International Phase 3, Randomized, Double-Blind, Active (Tolterodine)-Controlled Multicenter Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder Completed NCT03583372 Phase 3 Vibegron;placebos;Tolterodine Tartrate ER
13 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Definitive Phase III Study of the Effects of Ferric Citrate on Serum Phosphate in Subjects With End Stage Renal Disease Completed NCT01503736 Phase 3 ferric citrate;ferric citrate;ferric citrate
14 A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder Completed NCT02045862 Phase 3 Solifenacin succinate;Mirabegron;Placebo to match solifenacin;Placebo to match mirabegron
15 A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms Completed NCT01908829 Phase 3 mirabegron 25 mg;mirabegron 50 mg;solifenacin 5 mg;solifenacin 10 mg;mirabegron 25 mg matching placebo;mirabegron 50 mg matching placebo;solifenacin 5 mg matching placebo;solifenacin 10 mg matching placebo
16 A Multicenter, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Lomefloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults Completed NCT00258102 Phase 3 Levofloxacin
17 A Multicenter, Double-Blind, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Ciprofloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults Completed NCT00258089 Phase 3 Levofloxacin
18 A Multicenter, Randomized, Open‐Label, Active‐Controlled, Parallel Study to Assess the Efficacy and Safety of Ferric Citrate Capsules for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis Recruiting NCT03984760 Phase 3 Ferric Citrate;Sevelamer Carbonate
19 Perioperative Pregabalin as Part of a Multimodal Treatment Plan for Pain After Ureteroscopy With Stent Placement: a Pilot Active, not recruiting NCT03927781 Phase 3 Pregabalin 300mg
20 An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria Enrolling by invitation NCT04042402 Phase 3 DCR-PHXC
21 A PHASE 3B, RANDOMIZED, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MAINTENANCE THERAPY WITH VALRUBICIN VERSUS NO MAINTENANCE, IN SUBJECTS TREATED WITH VALRUBICIN INDUCTION FOR CARCINOMA IN SITU (CIS) OF THE BLADDER Terminated NCT01310803 Phase 3 VALSTAR - Maintenance Therapy
22 A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB) Terminated NCT00384891 Phase 3 Bacillus Calmette-Guérin
23 A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer Terminated NCT01200992 Phase 3
24 A Multi-Centre, Randomised, Open-Label Active-Controlled Study Comparing Safety and Efficacy of Synergo Radiofrequency (RF)-Induced Hyperthermia-Chemotherapy With Mitomycin C (RITE) Versus Bacillus Calmette-Guérin (BCG) as First-Line Treatment of Non-Muscle Invasive Papillary Bladder Cancer (NMIBC) Withdrawn NCT02254915 Phase 3 Bacillus Calmette-Guérin
25 Randomized Controlled Trial of Fetal Cystoscopy Versus Vesico-amniotic Shunting in Severe Lower Urinary Tract Obstructions Unknown status NCT01552824 Phase 2
26 A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder. Completed NCT01340027 Phase 2 Mirabegron;Solifenacin succinate;Placebo
27 A Multicenter, Single-Arm Study of the Effects of Atrasentan on Spermatogenesis and Testicular Function Completed NCT02118714 Phase 2 Atrasentan
28 RTA 402 Phase 2 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Chronic Kidney Disease and Type 2 Diabetes) Completed NCT02316821 Phase 2 RTA 402;Placebo
29 Muscle Cell Mediated Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery: An Investigation of Cook MyoSite Autologous Muscle Derived Cells Completed NCT02291432 Phase 1, Phase 2
30 A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of Female Patients With Bladder Pain Syndrome / Interstitial Cystitis Completed NCT01613586 Phase 2 ASP3652;Placebo
31 Evaluation of the Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel Mixed With Mitomycin C (MMC) in Non-muscle Invasive Bladder Cancer (NMIBC) Patients Completed NCT02307487 Phase 2 120 mg MMC in 90ml gel;140 mg MMC in 90ml gel;160 mg MMC in 90ml gel;120 mg MMC in 60ml gel;140 mg MMC in 60ml gel;160 mg MMC in 60ml gel
32 A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Urinary Tract Infection (cUTI) Completed NCT01505634 Phase 2 Relebactam 250 mg;Relebactam 125 mg;imipenem/cilastatin 500 mg;Placebo to relebactam;Ciprofloxacin
33 A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria Recruiting NCT03847909 Phase 2 DCR-PHXC;Sterile Normal Saline (0.9% NaCl)
34 A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer Recruiting NCT03081858 Phase 1, Phase 2 TSD-001
35 Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II. Recruiting NCT03562897 Phase 2
36 A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Administration of ALN-GO1 in Patients With Primary Hyperoxaluria Type 1 Active, not recruiting NCT03350451 Phase 2 Lumasiran
37 A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease Not yet recruiting NCT04387448 Phase 2 GFB-887;Placebo
38 A Dose Escalation, Expansion Study of Vofatamab (B-701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects With Locally Advanced or Metastatic Urothelial Cell Carcinoma Who Have Relapsed After, or Are Refractory to Standard Therapy Terminated NCT02401542 Phase 1, Phase 2 Vofatamab;Docetaxel;Placebo
39 A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Interstitial Cystitis/ Painful Bladder Syndrome Terminated NCT01060254 Phase 2 Placebo;JNJ-42160443
40 A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined With Pembrolizumab in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Who Have Progressed Following Platinum-based Chemotherapy Terminated NCT03123055 Phase 1, Phase 2 B-701;Pembrolizumab
41 Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients Completed NCT01232010 Phase 1 Mirodenafil
42 Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients Completed NCT01231997 Phase 1 Udenafil
43 A First-In-Human, Phase 1, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GFB-887, a TRPC5 Channel Inhibitor, in Healthy Subjects Completed NCT03970122 Phase 1 GFB-887;Placebo
44 A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fed State in Healthy Adult Male Subjects Completed NCT02058576 Phase 1 Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg;Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
45 A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fasted State in Healthy Adult Male Subjects Completed NCT02052713 Phase 1 Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg;Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
46 A Phase I Study for the Evaluation of Safety and Efficacy of Humacyte's Human Acellular Vascular Graft for Use as a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease Completed NCT01840956 Phase 1
47 A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934/V935 hTERT Vaccination in Cancer Patients With Selected Solid Tumors Completed NCT00753415 Phase 1
48 Pilot Study of Mycophenolate Mofetil in Congenital Uropathies Completed NCT00193635 Phase 1 mycophenolate mofetil
49 Serial Amnioinfusions as Regenerative Therapy for Pulmonary Hypoplasia in Fetuses With Intrauterine Renal Failure or Severe Renal Anomalies- a Feasibility Study Recruiting NCT03723564 Phase 1 Lactated Ringers Solution for Injection
50 A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAS-102 in Patients With Advanced Solid Tumors and Varying Degrees of Renal Impairment Active, not recruiting NCT02301117 Phase 1 TAS-102

Search NIH Clinical Center for Lower Urinary Tract Obstruction, Congenital

Cochrane evidence based reviews: urologic diseases

Genetic Tests for Lower Urinary Tract Obstruction, Congenital

Anatomical Context for Lower Urinary Tract Obstruction, Congenital

MalaCards organs/tissues related to Lower Urinary Tract Obstruction, Congenital:

40
Kidney, Prostate, Brain, Testes

Publications for Lower Urinary Tract Obstruction, Congenital

Articles related to Lower Urinary Tract Obstruction, Congenital:

(show top 50) (show all 80)
# Title Authors PMID Year
1
Rare Variants in BNC2 Are Implicated in Autosomal-Dominant Congenital Lower Urinary-Tract Obstruction. 56 6 61
31051115 2019
2
Antenatal intervention for congenital fetal lower urinary tract obstruction (LUTO): a systematic review and meta-analysis. 61
30501534 2020
3
Fetal anesthesia: intrauterine therapies and immediate postnatal anesthesia for noncardiac surgical interventions. 61
32324666 2020
4
Fetal lower urinary tract obstruction: What should we tell the prospective parents? 61
32065667 2020
5
Neurodevelopmental Outcome in Infants with Lower Urinary Tract Obstruction Based on Different Degrees of Severity. 61
32146466 2020
6
Fetal Cystoscopy and Vesicoamniotic Shunting in Lower Urinary Tract Obstruction: Long-Term Outcome and Current Technical Limitations. 61
31401627 2020
7
Prediction model of postnatal renal function in fetuses with lower urinary tract obstruction (LUTO)-Development and internal validation. 61
31659787 2019
8
Fetal cardiac findings and hemodynamic changes associated with severe lower urinary tract obstruction in utero. 61
30908816 2019
9
Balloon catheterization in fetal lower urinary tract obstruction: an observational study of 10 fetuses. 61
31763721 2019
10
Outcome of fetuses with lower urinary tract obstruction and normal amniotic fluid volume in second trimester of pregnancy. 61
30977189 2019
11
Congenital urinary tract obstruction. 61
30819578 2019
12
Fetal megacystis: a lot more than LUTO. 61
30043466 2019
13
Myocardial function in fetuses with lower urinary tract obstruction: Is there a cardiac remodeling effect due to renal damage? 61
30957256 2019
14
First-year profile of biomarkers for early detection of renal injury in infants with congenital urinary tract obstruction. 61
30694385 2019
15
The role of renal biomarkers to predict the need of surgery in congenital urinary tract obstruction in infants. 61
30979613 2019
16
Biometric and morphological features of the fetal bladder in lower urinary tract obstruction on magnetic resonance imaging: new perspectives for fetal cystoscopy. 61
31006924 2019
17
Surgical interventions and anesthesia in the 1st year of life for lower urinary tract obstruction. 61
30049573 2019
18
A classic twin study of lower urinary tract obstruction: Report of 3 cases and literature review. 61
29664229 2019
19
Antenatal staging of congenital lower urinary tract obstruction. 61
29978555 2019
20
Neonatal survival and kidney function after prenatal interventions for obstructive uropathies. 61
31392712 2019
21
Effectiveness of Prenatal Intervention on the Outcome of Diseases That Have a Postnatal Urological Impact. 61
31001504 2019
22
Prenatal diagnosis of LUTO: improving diagnostic accuracy. 61
29266464 2018
23
Long-term renal outcome in infants with congenital lower urinary tract obstruction. 61
29980359 2018
24
Perinatal Outcomes of Fetal Lower Urinary Tract Obstruction After Vesicoamniotic Shunting Using a Double-Basket Catheter. 61
29498072 2018
25
Prenatal renal parenchymal area as a predictor of early end-stage renal disease in children with vesicoamniotic shunting for lower urinary tract obstruction. 61
30093259 2018
26
Fetal surgery for lower urinary tract obstruction: the importance of staging prior to intervention. 61
29160637 2018
27
Comparison of biochemical analysis of fetal serum and fetal urine in the prediction of postnatal renal outcome in lower urinary tract obstruction. 61
29644715 2018
28
Natural History of Fetal Lower Urinary Tract Obstruction with Normal Amniotic Fluid Volume at Initial Diagnosis. 61
28700992 2018
29
Lower urinary tract obstruction: fetal intervention based on prenatal staging. 61
28730376 2017
30
Report on The Society for Fetal Urology panel discussion on the selection criteria and intervention for fetal bladder outlet obstruction. 61
28476482 2017
31
Effectiveness of vesicoamniotic shunt in fetuses with congenital lower urinary tract obstruction: an updated systematic review and meta-analysis. 61
27270578 2017
32
Finding pathways to national-scale land-sector sustainability. 61
28406202 2017
33
Incidence and Risk Factors of De novo Stress Urinary Incontinence after Pelvic Floor Reconstruction: A Nested Case-control Study. 61
28303850 2017
34
Evidence Suggesting the End of Universal Domestic Asbestos Exposure in Metsovo, NW Greece. 61
29020669 2017
35
Serial amnioinfusions for fetal pulmonary palliation in fetuses with renal failure. 61
26978650 2017
36
Early vesico-amniotic shunting - does it change the prognosis in fetal lower urinary tract obstruction diagnosed in the first trimester? 61
29057434 2017
37
Ultrasound guided balloon catheterisation: a new method of fetal lower urinary tract obstruction management. 61
28580571 2017
38
Are ultrasound renal aspects associated with urinary biochemistry in fetuses with lower urinary tract obstruction? 61
27862070 2016
39
Fetal lower urinary tract obstruction: proposal for standardized multidisciplinary prenatal management based on disease severity. 61
26690832 2016
40
Vesico-amniotic shunting for lower urinary tract obstruction in a fetus with VACTERL association. 61
27061706 2016
41
Factors associated with fetal shunt dislodgement in lower urinary tract obstruction. 61
27247093 2016
42
Factors associated with the grief after stillbirth: a comparative study between Brazilian and Canadian women. 61
27680038 2016
43
Taking care of the newborn dying and their families: Nurses' experiences of neonatal intensive care. 61
27384286 2016
44
Defining and predicting 'intrauterine fetal renal failure' in congenital lower urinary tract obstruction. 61
26525197 2016
45
Two-year outcomes after diagnostic and therapeutic fetal cystoscopy for lower urinary tract obstruction. 61
26739350 2016
46
Current applications of in utero intervention for lower urinary tract obstruction. 61
26441047 2015
47
Outcome in fetal lower urinary tract obstruction: a prospective registry study. 61
25689128 2015
48
Fetal urine biochemistry at 13-23 weeks of gestation in lower urinary tract obstruction: criteria for in-utero treatment. 61
25412852 2015
49
Fetal intervention for severe lower urinary tract obstruction: a multicenter case-control study comparing fetal cystoscopy with vesicoamniotic shunting. 61
25157756 2015
50
Fetal Lower Urinary Tract Obstruction (LUTO): a practical review for providers. 61
27057343 2015

Variations for Lower Urinary Tract Obstruction, Congenital

ClinVar genetic disease variations for Lower Urinary Tract Obstruction, Congenital:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 BNC2 NM_017637.6(BNC2):c.2663A>G (p.His888Arg)SNV Pathogenic 599348 rs1563774686 9:16419624-16419624 9:16419626-16419626
2 BNC2 NM_017637.6(BNC2):c.2636+499C>TSNV Pathogenic 624566 rs1350162888 9:16435054-16435054 9:16435056-16435056

UniProtKB/Swiss-Prot genetic disease variations for Lower Urinary Tract Obstruction, Congenital:

73
# Symbol AA change Variation ID SNP ID
1 BNC2 p.His888Arg VAR_083495

Expression for Lower Urinary Tract Obstruction, Congenital

Search GEO for disease gene expression data for Lower Urinary Tract Obstruction, Congenital.

Pathways for Lower Urinary Tract Obstruction, Congenital

GO Terms for Lower Urinary Tract Obstruction, Congenital

Sources for Lower Urinary Tract Obstruction, Congenital

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....